Key result
SGLT2 inhibitor prescriptions for chronic kidney disease are subject to gender disparities, highlighting the need for actionable interventions to ensure equitable care.
Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Highlights the need to address gender disparities in the prescription of SGLT2 inhibitors for patients with chronic kidney disease.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ömer Faruk Akçay (2025) studied this question. SGLT2 inhibitor prescriptions for chronic kidney disease are subject to gender disparities, highlighting the need for actionable interventions to ensure equitable care.
Synapse has enriched 10 related papers. Consider them for comparative context: